trilliant health glp-1 prescriptions 2024 GLP-1s Are Reshaping Healthcare, But We Can't Let Cost Outrun Value GLP-1 Prescribing Is Rising —

The postbiotic needs a healthy gut environment to work with

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

The GLP-1R and GIPR pathways both converge on beta cell function through incretin signaling, and retatrutide provides a tool to study the amplified incretin response that occurs when both receptors are activated simultaneously

This change contributed amino acid, acetic acid, and BCAA concentrations to be increased, and energy metabolism pathway was also increased at in vivo and in vitro

See open roles

Most research shows diet soda can make you gain weight